CHK2 antibody
Principal name
CHK2 antibody
Alternative names for CHK2 antibody
CHEK2, CHEK-2, CHK-2, RAD53, Cds1, Serine/threonine-protein kinase Chk2, CHK2 checkpoint homolog
Ncbi ID
NP_001005735.1, NP_001005735, 9606, O96017, NM_001005735, NP_009125, NM_007194, NP_057890.1, NM_016681, NM_145862
Available reactivities
Available hosts
Available applications
Enzyme Immunoassay (E), Paraffin Sections (P), Western blot / Immunoblot (WB), Immunocytochemistry/Immunofluorescence (ICC/IF), EPair for Elisa (EPair), ELISA (detection) (E(detection)), Immunoprecipitation (IP), Flow Cytometry (F), Luminex (LMNX), Frozen Sections (C)
Background of CHK2 antibody
In response to DNA damage and replication blocks, cell cycle progression is halted through the control of critical cell cycle regulators. CHEK2 is a cell cycle checkpoint regulator and putative tumor suppressor. It contains a forkhead-associated protein interaction domain essential for activation in response to DNA damage and is rapidly phosphorylated in response to replication blocks and DNA damage. When activated, CHEK2 is known to inhibit CDC25C phosphatase, preventing entry into mitosis, and has been shown to stabilize the tumor suppressor protein p53, leading to cell cycle arrest in G1. In addition, this protein interacts with and phosphorylates BRCA1, allowing BRCA1 to restore survival after DNA damage. Mutations in its gene have been linked with Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. Also, mutations in its gene are thought to confer a predisposition to sarcomas, breast cancer, and brain tumors. This nuclear protein is a member of the CDS1 subfamily of serine/threonine protein kinases.In response to DNA damage and replication blocks, cell cycle progression is halted through the control of critical cell cycle regulators. The protein encoded by this gene is a cell cycle checkpoint regulator and putative tumor suppressor. It contains a forkhead-associated protein interaction domain essential for activation in response to DNA damage and is rapidly phosphorylated in response to replication blocks and DNA damage. When activated, the encoded protein is known to inhibit CDC25C phosphatase, preventing entry into mitosis, and has been shown to stabilize the tumor suppressor protein p53, leading to cell cycle arrest in G1. In addition, this protein interacts with and phosphorylates BRCA1, allowing BRCA1 to restore survival after DNA damage. Mutations in this gene have been linked with Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. Also, mutations in this gene are thought to confer a predisposition to sarcomas, breast cancer, and brain tumors. This nuclear protein is a member of the CDS1 subfamily of serine/threonine protein kinases. Three transcript variants encoding different isoforms have been found for this gene.
General readings
Clone DCS-273 is used in these references:
1. Syljuäsen, R.G., et al., Cancer Res. 66, 10253-10257 (2006)
2. Berger, M., et al., Mol. Cell Biol. 25, 5380-5388 (2005)
3. Latella, L., et al., Mol. Cell Biol. 24, 6350-6361 (2004)
4. Louria-Hayon, I., et al., J. Biol. Chem. 278, 33134-33141 (2003)
5. Lukas, C., et al., Cancer Res. 61, 4990-4993 (2001)







Lane1:Hela cell lysate
Lane2:Mouse liver tissue lysate
Lane3:Rat spleen tissue lysate


Lane1:MCF-7 cell lysate
Lane2:Mouse liver tissue lysate
Lane3:Rat liver tissue lysate






























































































































Mouse Lenti ORF Particles
| Catalog No. | ||
|---|---|---|
| MR208692L2V | Lenti ORF particles, Chek2 (GFP-tagged) - Mouse CHK2 checkpoint homolog (S. pombe) (Chek2), 200 uL, >10^7 TU/mL |
|
![]() |
200 µl /
€1,250.00
|
|
| OriGene Technologies, Inc. | ||
| MR208692L1V | Lenti ORF particles, Chek2 (Myc-DDK-tagged) - Mouse CHK2 checkpoint homolog (S. pombe) (Chek2), 200 uL, >10^7 TU/mL |
|
![]() |
200 µl /
€1,120.00
|
|
| OriGene Technologies, Inc. | ||



































